Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0336640/Ulcerative-Colitis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Ulcerative Colitis Therapeutics market. The report identifies the key trends shaping and driving the global Ulcerative Colitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Ulcerative Colitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Ulcerative Colitis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Ulcerative Colitis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Ulcerative Colitis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Ulcerative Colitis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Ulcerative Colitis Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Ulcerative Colitis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Ulcerative Colitis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Ulcerative Colitis Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Overview 7
2.2 Epidemiology 7
2.3 Etiology and Pathophysiology 7
2.4 Signs and Symptoms 8
2.5 Diagnosis 9
2.6 Treatment and Management Pattern 10
2.7 GlobalData Pipeline Report Guidance 14
3 Ulcerative Colitis Therapeutics - Market Characterization 15
3.1 Ulcerative Colitis Therapeutics Market Size (2005-2010) - Global 15
3.2 Ulcerative Colitis Therapeutics Market Forecast (2010-2018) - Global 16
3.3 Ulcerative Colitis Therapeutics Market Size (2005-2010) - The US 17
3.4 Ulcerative Colitis Therapeutics Market Forecast (2010-2018) - The US 18
3.5 Ulcerative Colitis Therapeutics Market Size (2005-2010) - France 19
3.6 Ulcerative Colitis Therapeutics Market Forecast (2010-2018) - France 20
3.7 Ulcerative Colitis Therapeutics Market Size (2005-2010) - Germany 21
3.8 Ulcerative Colitis Therapeutics Market Forecast (2010-2018) - Germany 22
3.9 Ulcerative Colitis Therapeutics Market Size (2005-2010) - Italy 23
3.10 Ulcerative Colitis Therapeutics Market Forecast (2010-2018) - Italy 24
3.11 Ulcerative Colitis Therapeutics Market Size (2005-2010) - Spain 25
3.12 Ulcerative Colitis Therapeutics Market Forecast (2010-2018) - Spain 26
3.13 Ulcerative Colitis Therapeutics Market Size (2005-2010) - The UK 27
3.14 Ulcerative Colitis Therapeutics Market Forecast (2010-2018) - The UK 28
3.15 Ulcerative Colitis Therapeutics Market Size (2005-2010) - Japan 29
3.16 Ulcerative Colitis Therapeutics Market Forecast (2010-2018) - Japan 30
3.17 Drivers and Barriers for the Ulcerative Colitis Therapeutics Market 31
3.17.1 Drivers for the Ulcerative Colitis Therapeutics Market 31
3.17.2 Barriers for the Ulcerative Colitis Therapeutics Market 31
3.18 Opportunity and Unmet Need Analysis 32
3.19 Key Takeaway 35
4 Ulcerative Colitis Therapeutics - Competitive Assessment 36
4.1 Overview 36
4.2 Strategic Competitor Assessment 36
4.3 Key Takeaway 37
4.4 Product Profiles for the Major Marketed Products in the Ulcerative Colitis Therapeutics Market-First Line Treatment Agents 38
4.4.1 Asacol (mesalamine) 38
4.4.2 Lialda (mesalamine) 39
4.4.3 Apriso (mesalamine) 39
4.4.4 Pentasa (mesalamine) 40
4.5 Product Profiles for the Major Marketed Products in the Ulcerative Colitis Therapeutics Market- Second Line Treatment Agents 40
4.5.1 Azulfidine (sulfasalazine) 40
4.5.2 Colazal (balsalazide) 41
4.6 Product Profiles for the Major Marketed Products in the Ulcerative Colitis Therapeutics Market-Fourth Line treatment Agent 41
4.6.1 Remicade 41
4.7 Key Takeaway 42
5 Ulcerative Colitis Therapeutics - Pipeline Assessment 43
5.1 Overview 43
5.2 Strategic Pipeline Assessment 43
5.3 Ulcerative Colitis Therapeutics Pipeline Analysis - Pipeline by Clinical Phases of Development 43
5.3.1 Ulcerative Colitis Therapeutics -New Drug Application (NDA) Filed 44
5.3.2 Ulcerative Colitis Therapeutics - Phase III Clinical Pipeline 44
5.3.3 Ulcerative Colitis Therapeutics - Phase II Clinical Pipeline 44
5.3.4 Ulcerative Colitis Therapeutics - Phase I/II Clinical Pipeline 45
5.3.5 Ulcerative Colitis Therapeutics - Phase I Clinical Pipeline 45
5.3.6 Ulcerative Colitis Therapeutics - Preclinical Pipeline 45
5.3.7 Ulcerative Colitis Therapeutics - Discovery Pipeline 45
5.4 Ulcerative Colitis Therapeutics Market - Clinical Pipeline by Mechanism of Action 46
5.5 Ulcerative Colitis Therapeutics, Other Promising Mechanisms of Action 47
5.6 Ulcerative Colitis Therapeutics Technology Trends Analytical Framework 48
5.7 Ulcerative Colitis Therapeutics - Promising Drugs under Clinical Development 49
5.8 Molecule Profile for Promising Drugs under Clinical Development 50
5.8.1 Humira (adalimumab) 50
5.8.2 Budesonide MMX 50
5.8.3 Vedolizumab (MLN 0002) 51
5.8.4 Simponi (golimumab) 51
5.8.5 Orencia (abatacept) 52
6 Ulcerative Colitis Therapeutics - Clinical Trials Mapping 53
6.1 Clinical Trials by Country 53
6.2 Clinical Trials by Phase 54
6.3 Clinical Trials by Trial Status 55
6.4 Overall Sponsors 56
6.5 Prominent Sponsors 57
6.6 Top Companies Participating in Therapeutics Clinical Trials 58
7 Ulcerative Colitis Therapeutics - Strategic Assessment 59
7.1 Key Events Impacting on the Future Market 59
7.2 Future Market Competition Scenario 60
8 Ulcerative Colitis Therapeutics - Future Players 61
8.1 Introduction 61
8.2 Abbott Laboratories 61
8.2.1 Company Overview 61
8.2.2 Financial Overview 62
8.2.3 Business Description 62
8.2.4 Autoimmune Disease Pipeline 62
8.2.5 Deals 63
8.3 Cosmo Pharmaceuticals S.p.A 64
8.3.1 Company Overview 64
8.3.2 Financial Overview 64
8.3.3 Autoimmune Disease Pipeline 64
8.3.4 Deals 64
8.4 Santarus, Inc. 65
8.4.1 Company Overview 65
8.4.2 Financial Overview 65
8.4.3 Autoimmune Disease Pipeline 65
8.4.4 Deals 65
8.5 Centocor Ortho Biotech, Inc 66
8.5.1 Company Overview 66
8.5.2 Business Overview 66
8.5.3 Autoimmune Disease Pipeline 66
8.5.4 Deals 67
8.6 Takeda Pharmaceutical Company Limited 68
8.6.1 Company Overview 68
8.6.2 Financial Overview 68
8.6.3 Business Description 68
8.6.4 Autoimmune Disease Pipeline 69
8.6.5 Deals 69
8.7 Other Companies in the Ulcerative Colitis Therapeutics Market 72
9 Ulcerative Colitis Therapeutics - Licensing and Partnership Deals 74
10 Ulcerative Colitis Therapeutics Market - Appendix 78
10.1 Definitions 78
10.2 Acronyms 78
10.3 Research Methodology 79
10.3.1 Coverage 79
10.3.2 Secondary Research 79
10.3.3 Forecasting 80
10.3.4 Primary Research 82
10.3.5 Expert Panel Validation 82
10.4 Contact Us 82
10.5 Disclaimer 82
10.6 Sources 83
List of Tables
Table 1: Ulcerative Colitis Therapeutics Market, Global, Revenue ($bn), 2005-2010 15
Table 2: Ulcerative Colitis Therapeutics Market, Global, Forecast ($bn), 2010-2018 16
Table 3: Ulcerative Colitis Therapeutics Market, The US, Revenue ($m), 2005-2010 17
Table 4: Ulcerative Colitis Therapeutics Market, The US, Forecasts ($m), 2010-2018 18
Table 5: Ulcerative Colitis Therapeutics Market, France, Revenue ($m), 2005-2010 19
Table 6: Ulcerative Colitis Therapeutics Market, France, Forecast ($m), 2010-2018 20
Table 7: Ulcerative Colitis Therapeutics Market, Germany, Revenue($m), 2005-2010 21
Table 8: Ulcerative Colitis Therapeutics Market, Germany, Forecast ($m), 2010-2018 22
Table 9: Ulcerative Colitis Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Table 10: Ulcerative Colitis Therapeutics Market, Italy, Forecast ($m), 2010-2018 24
Table 11: Ulcerative Colitis Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Table 12: Ulcerative Colitis Therapeutics Market, Spain, Forecast ($m), 2010-2018 26
Table 13: Ulcerative Colitis Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Table 14: Ulcerative Colitis Therapeutics Market, the UK, Forecast ($m), 2010-2018 28
Table 15: Ulcerative Colitis Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Table 16: Ulcerative Colitis Therapeutics Market, Japan, Forecast ($m), 2010-2018 30
Table 17: Ulcerative Colitis Therapeutics - NDA Filed, 2011 44
Table 18: Ulcerative Colitis Therapeutics- Phase III Clinical Pipeline, 2011 44
Table 19: Ulcerative Colitis Therapeutics - Phase II Clinical Pipeline, 2011 44
Table 20: Ulcerative Colitis Therapeutics - Phase I/II Clinical Pipeline, 2011 45
Table 21: Ulcerative Colitis Therapeutics - Phase I Clinical Pipeline, 2011 45
Table 22: Ulcerative Colitis Therapeutics- Preclinical Pipeline, 2011 45
Table 23: Ulcerative Colitis Therapeutics-Discovery Pipeline, 2011 45
Table 24: Mechanisms of action that constitute the others in the Pie-chart in Figure 33 47
Table 25: Ulcerative Colitis Therapeutics - Most Promising Drugs Under Clinical Development, 2011 49
Table 26: Ulcerative Colitis Therapeutics - Clinical Trials by Country, 2011 53
Table 27: Ulcerative Colitis Therapeutics - Clinical Trials by Phase, 2011 54
Table 28: Ulcerative Colitis Therapeutics - Clinical Trials by Trial Status, 2011 55
Table 29: Ulcerative Colitis Therapeutics - Prominent Sponsors, 2011 57
Table 30: Ulcerative Colitis Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 58
Table 31: Abbott Laboratories -Autoimmune diseases, Pipeline, 2011 62
Table 32: Abbott - Ulcerative Colitis Therapeutics Pipeline, 2011 62
Table 33: Abbott Laboratories, Deals, 2009-2011 63
Table 34: Cosmo Pharmaceuticals-Autoimmune diseases, Pipeline, 2011 64
Table 35: Cosmo Pharmaceuticals - Ulcerative Colitis Therapeutics Pipeline, 2011 64
Table 36: Cosmo Pharmaceuticals, Deals, 2009-2011 64
Table 37: Santarus Inc. -Autoimmune diseases, Pipeline, 2011 65
Table 38: Santarus Inc, Deals, 2009-2011 65
Table 39: Centocor (J&J) - Autoimmune Diseases Pipeline, 2011 66
Table 40: Centocor (J&J) - Ulcerative Colitis Therapeutics Pipeline, 2011 67
Table 41: Centocor (J&J) , Deals, 2009-2011 67
Table 42: Takeda Pharmaceutical Company Autoimmune Diseases Pipeline, 2011 69
Table 43: Takeda Pharmaceutical Company - Ulcerative Colitis Therapeutics Pipeline, 2011 69
Table 44: Takeda Pharmaceutical Company , Deals, 2009-2011 69
Table 45: Ulcerative Colitis Therapeutics Market- Future Players 72
Table 46: Ulcerative Colitis Therapeutics Market, Global, Deals, 2011 74
List of Figures
Figure 1: Ulcerative Colitis Therapeutics - Histology of Ulcerative Colitis 8
Figure 2: Ulcerative Colitis Therapeutics - Severity Index of Disease 8
Figure 3: 5-Aminosalicylates - Advantages and Disadvantages 11
Figure 4: Corticosteroids - Advantages and Disadvantages 11
Figure 5: Immunomodulators - Advantages and Disadvantages 12
Figure 6: Biologics - Advantages and Disadvantages 12
Figure 7: Ulcerative Colitis Therapeutics - Pyramid Approach of Treatment 13
Figure 8: Ulcerative Colitis Therapeutics Market, Global, Revenue ($bn), 2005-2010 15
Figure 9: Ulcerative Colitis Therapeutics Market, Global, Forecast ($bn), 2010-2018 16
Figure 10: Ulcerative Colitis Therapeutics Market, The US, Revenue ($m), 2005-2010 17
Figure 11: Ulcerative Colitis Therapeutics Market, The US, Forecast ($m), 2010-2018 18
Figure 12: Ulcerative Colitis Therapeutics Market, France, Revenue ($m), 2005-2010 19
Figure 13: Ulcerative Colitis Therapeutics Market, France, Forecast ($m), 2010-2018 20
Figure 14: Ulcerative Colitis Therapeutics Market, Germany, Revenue($m), 2005-2010 21
Figure 15: Ulcerative Colitis Therapeutics Market, Germany, Forecast ($m), 2010-2018 22
Figure 16: Ulcerative Colitis Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Figure 17: Ulcerative Colitis Therapeutics Market, Italy, Forecast ($m), 2010-2018 24
Figure 18: Ulcerative Colitis Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Figure 19: Ulcerative Colitis Therapeutics Market, Spain, Forecast ($m), 2010-2018 26
Figure 20: Ulcerative Colitis Therapeutics Market, the UK, Revenue ($m), 2005-2010 27
Figure 21: Ulcerative Colitis Therapeutics Market, The UK, Forecast ($m), 2010-2018 28
Figure 22: Ulcerative Colitis Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Figure 23: Ulcerative Colitis Therapeutics Market, Japan, Forecast ($m), 2010-2018 30
Figure 24: Opportunity and Unmet Need - First-Line Treatment in Ulcerative Colitis 32
Figure 25: Opportunity and Unmet Need - Second-Line Treatment in Ulcerative Colitis 33
Figure 26: Opportunity and Unmet Need - Third-Line Treatment in Ulcerative Colitis 34
Figure 27: Opportunity and Unmet Need - Fourth-Line Treatment in Ulcerative Colitis 35
Figure 28: Ulcerative Colitis Therapeutics Market - First-Line Treatment Agents, Strategic Competitor Assessment, 2011 36
Figure 29: Ulcerative Colitis Therapeutics Market - Second-Line Treatment Agents - Strategic Competitor Assessment, 2011 37
Figure 30: Ulcerative Colitis Therapeutics Market -Fourth-Line Treatment Agents , Strategic Competitor Assessment, 2011 37
Figure 31: Ulcerative Colitis Therapeutics - Pipeline by Phase of Clinical Development, 2011 43
Figure 32: Ulcerative Colitis Therapeutics, Clinical Pipeline by Mechanism Of Action, 2011 46
Figure 33: Ulcerative Colitis Therapeutics, Technology Trends Analytics Framework, 2011 48
Figure 34: Ulcerative Colitis Therapeutics, Technology Trends Analytics Framework, Description, 2011 49
Figure 35: Ulcerative Colitis Therapeutics - Clinical Trials by Country, 2011 53
Figure 36: Ulcerative Colitis Therapeutics - Clinical Trials by Phase, 2011 54
Figure 37: Ulcerative Colitis Therapeutics - Clinical Trials by Status, 2011 55
Figure 38: Ulcerative Colitis Therapeutics - Overall Sponsors, 2011 56
Figure 39: Ulcerative Colitis Therapeutics - Prominent Sponsors, 2011 57
Figure 40: Ulcerative Colitis Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 58
Figure 41: Ulcerative Colitis Therapeutics Market, Drivers and Restraints, 2011 59
Figure 42: Implications for Future Market Competition in Ulcerative Colitis Therapeutic Market, 2011 60
Figure 43: Ulcerative Colitis Therapeutics Market, Pipeline by Company, 2011 61
Figure 44: GlobalData Market Forecasting Model 81
Companies Mentioned
Abbott Laboratories
Cosmo Pharmaceuticals S.p.A
Santarus, Inc.
Centocor Ortho Biotech, Inc
Takeda Pharmaceutical Company Limited
To order this report:
Pathology Industry: Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Pathology Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article